FOXO4-DRI in Australia: legal status and listed suppliers

Legal status in Australia

Not an approved medicine. Not listed by name in the Poisons Standard (June 2026).

As understood at 2026-09-22. Verify with the TGA.

What FOXO4-DRI is

FOXO4-DRI is a synthetic peptide designed in 2017 by a group at Erasmus MC in the Netherlands to kill senescent cells, the damaged cells that stop dividing but accumulate with age. It copies a stretch of the FOXO4 protein but is built from D-amino acids in reverse order, which makes it resistant to breakdown, and carries a cell-penetrating tag. It is a research compound; no human trials have been published.

Full FOXO4-DRI page: targets and research →

Listed suppliers in Australia

None of the suppliers we list in Australia list FOXO4-DRI.

Clinical Research

Targeted Apoptosis of Senescent Cells Restores Tissue Homeostasis in Response to Chemotoxicity and Aging

Baar MP, Brandt RMC, Putavet DA, et al. (2017). Cell. animal cultured senescent cells; fast-ageing (XpdTTD/TTD) and naturally aged mice

FOXO4-DRI alleviates age-related testosterone secretion insufficiency by targeting senescent Leydig cells in aged mice

Zhang C, Xie Y, Chen H, et al. (2020). Aging. animal senescent TM3 Leydig cells in culture; naturally aged mice

FOXO4-DRI regulates endothelial cell senescence via the P53 signaling pathway

Hu Z, Li F, Hu C, et al. (2026). Frontiers in Bioengineering and Biotechnology. animal naturally aged and progeroid mice; cultured endothelial cells under oxygen-glucose deprivation

Senolytic Peptide FOXO4-DRI Selectively Removes Senescent Cells From in vitro Expanded Human Chondrocytes

Huang Y, He Y, Makarcyzk MJ, Lin H (2021). Frontiers in Bioengineering and Biotechnology. in-vitro human cartilage cells from healthy donors, expanded in culture